An interventional study of Atala™ lead in Ventricular Arrythmia, Ventricular Fibrillation and Ventricular Tachycardia, sponsored by AtaCor Medical, Inc.. Active, not recruiting at 3 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-04.
Sponsored by AtaCor Medical, Inc. · Not applicable, Interventional, and Treatment
The ASCEND EV Study is a prospective, multi-center, single-arm, non-randomized study without concurrent or historical controls. The purpose of the study is to evaluate the Investigational Devices through at least 3-months of follow-up to inform the design of a subsequent pivotal clinical investigation.
The objectives of the study are to: 1) preliminarily validate safety and effectiveness of the Atala™ lead as a permanent ICD lead when used with a compatible ICD pulse generator, 2) evaluate suitability of clinical study testing methods and 3) inform statistically powered primary safety and effectiveness endpoints in a subsequent pivotal clinical investigation.
The primary safety endpoint is freedom from major Adverse Device Effects (ADEs) through 3-months. The primary performance endpoint is successful induced ventricular arrhythmia (IVA) test in the final system configuration.
Up to three (3) Investigational Sites will participate with up to 35 Subjects enrolled in the study. Subjects who meet current indications for ICD therapy will be eligible for participation. Eligible Subjects will receive an Atala™ lead connected to a commercially available ICD positioned in a left pectoral or left lateral location.
The Atala™ lead will be connected to a compatible ICD pulse generator and tested to verify appropriate sensing and defibrillation. Abbreviated IVA testing will be performed at the 3-month follow-up visit to verify continued sensing and defibrillation effectiveness. Starting at 6 months, Subjects will be followed every 6 months until the study is closed. The study is expected to remain open for at least 3 years.
Endpoints will be analyzed and summarized in a final study report after all active Subjects have completed the 3-month visit.
Exclusion Criteria:
Known history of lung disease with FEV1 \< 1.0 Liter
Device Related:
Any known need for future MRI
Anatomy Related:
Surgically corrected congenital heart disease (not including catheter-based procedures)
Cardiac Related:
Patients with a medical condition that precludes them from undergoing defibrillation testing:
Subjects implanted with the Atala™ lead
Device: Atala™ lead
Subjects will receive the Atala™ lead being evaluated in the study.
Also known as: AtaCor EV-ICD Atala™ lead, AtaCor Atala™ lead
Freedom from major ADEs
Freedom from major Adverse Device Effects (ADEs)
Time frame: Through 3 months post-implant
Successful IVA Test
Successful induced ventricular arrhythmia (IVA) test in the final system configuration
Time frame: At the time of procedure
This study is active, not recruiting, as verified in Dec 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
AtaCor Medical, Inc.